Boehringer Ingelheim Corporation Forms JV With Presidio Pharmaceuticals, Inc.
3/13/2013 7:05:44 AM
More...
|
Biocryst Pharmaceuticals (BCRX), Presidio Pharmaceuticals, Inc. Call Off Proposed $101 Million Acquisition
11/30/2012 7:54:26 AM
More...
|
Biocryst Pharmaceuticals (BCRX) Snags Presidio Pharmaceuticals, Inc. for $101 Million
10/18/2012 6:54:12 AM
More...
|
Presidio Pharmaceuticals, Inc. Successfully Completes Phase 1 Proof-of-Concept for PPI-668, its Potent HCV NS5A Inhibitor, in Hepatitis C Patients With Genotype-1 Infection
6/26/2012 10:59:10 AM
More...
|
Presidio Pharmaceuticals, Inc. Announces a New Clinical Candidate, PPI-383, a Novel Pan-Genotypic Non-Nucleoside Polymerase Inhibitor for HCV
4/23/2012 10:23:50 AM
More...
|
Presidio Pharmaceuticals, Inc. Announces Phase 1a-1b Clinical Results with PPI-668, a Potent Pan-genotypic HCV NS5A Inhibitor
4/18/2012 10:47:29 PM
More...
|
Presidio Pharmaceuticals, Inc. Reports Progress with Hepatitis C Antiviral Programs
1/9/2012 6:15:48 AM
More...
|
Presidio Pharmaceuticals, Inc. Announces Clinical Proof-of-Concept Data for its First HCV NS5A Inhibitor, PPI-461, and Initiation of Clinical Testing for its Second-Generation NS5A Inhibitor, PPI-668
11/4/2011 6:40:08 AM
More...
|
Presidio Pharmaceuticals, Inc. Announces the Appointment of H. Daniel Perez, M.D. as President and Chief Executive Officer
10/25/2011 7:12:18 AM
More...
|
Presidio Pharmaceuticals, Inc. Announces Positive Results in a Phase 1b Clinical Trial of PPI-461, a Novel, Potent Broadly-Active Hepatitis C Virus (HCV) Inhibitor
3/30/2011 10:27:31 AM
More...
|
|